Go to
JCI Insight
Citations to this article
Alok K. Singh, … , Mihai G. Netea, William R. Bishai
Published June 1, 2021
Citation Information: J Clin Invest. 2021;131(11):e148291. https://doi.org/10.1172/JCI148291.
Citation Information: J Clin Invest. 2021;131(11):e148291. https://doi.org/10.1172/JCI148291.
Abstract
First administered to a human subject as a tuberculosis (TB) vaccine on July 18, 1921, Bacillus Calmette-Guérin (BCG) has a long history of use for the prevention of TB and later the immunotherapy of bladder cancer. For TB prevention, BCG is given to infants born globally across over 180 countries and has been in use since the late 1920s. With about 352 million BCG doses procured annually and tens of billions of doses having been administered over the past century, it is estimated to be the most widely used vaccine in human history. While its roles for TB prevention and bladder cancer immunotherapy are widely appreciated, over the past century, BCG has been also studied for nontraditional purposes, which include (a) prevention of viral infections and nontuberculous mycobacterial infections, (b) cancer immunotherapy aside from bladder cancer, and (c) immunologic diseases, including multiple sclerosis, type 1 diabetes, and atopic diseases. The basis for these heterologous effects lies in the ability of BCG to alter immunologic set points via heterologous T cell immunity, as well as epigenetic and metabolomic changes in innate immune cells, a process called “trained immunity.” In this Review, we provide an overview of what is known regarding the trained immunity mechanism of heterologous protection, and we describe the current knowledge base for these nontraditional uses of BCG.
Authors
Alok K. Singh, Mihai G. Netea, William R. Bishai
Citation information
Citations to this article (43)
| Title and authors | Publication | Year |
|---|---|---|
|
Tuberculosis vaccines and therapeutic drug: challenges and future directions
An Y, Ni R, Zhuang L, Yang L, Ye Z, Li L, Parkkila S, Aspatwar A, Gong W |
Molecular Biomedicine | 2025 |
|
An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants
Mambelli F, de Araujo AC, Farias JP, de Andrade KQ, Ferreira LC, Minoprio P, Leite LC, Oliveira SC |
Pathogens | 2025 |
|
Mycobacterium spp. exposure, childhood vaccinations, and early childhood brain and CNS cancers
Singh S, Singh RK |
Frontiers in Immunology | 2025 |
|
Deconvoluting the interplay of innate and adaptive immunity in BCG-induced nonspecific and TB-specific host resistance
Hilligan KL, Darrah PA, Seder RA, Sher A |
The Journal of Experimental Medicine | 2025 |
|
Beyond Adaptive Immunity: Trained Innate Immune Responses as a Novel Frontier in Hepatocellular Carcinoma Therapy
Hsieh CH, Chuang PC, Liu YW |
Cancers | 2025 |
|
Evaluation of combined BCG and SARS-CoV-2 vaccination for immune enhancement and lung protection in Syrian hamsters
Ashtari A, Nayeri Fasaei B, Taghizadeh M, Joghataei SM, Dabaghian M, Mosavari N, Eslampanah M, Arpanaei A |
Scientific Reports | 2025 |
|
BCG vaccination-induced acquired control of mycobacterial growth differs from growth control preexisting to BCG vaccination
van Meijgaarden KE, Li W, Moorlag SJ, Koeken VA, Koenen HJ, Joosten LA, Vyakarnam A, Ahmed A, Rakshit S, Adiga V, Ottenhoff TH, Li Y, Netea MG, Joosten SA |
Nature Communications | 2024 |
|
Vaccines and Dementia: Part I. Non-Specific Immune Boosting with BCG: History, Ligands, and Receptors.
Greenblatt CL, Lathe R |
Journal of Alzheimer's disease : JAD | 2024 |
|
Mycobacterium bovis BCG as immunostimulating agent prevents the severe form of chronic experimental Chagas disease
Arce-Fonseca M, Mata-Espinosa D, Aranda-Fraustro A, Rosales-Encina JL, Flores-Valdez MA, Rodríguez-Morales O |
Frontiers in immunology | 2024 |
|
Efficacy of Bacillus Calmette-Guérin in Cancer Prevention and Its Putative Mechanisms
Gupta S, Yadav S, Kumar P |
Journal of Cancer Prevention | 2024 |
|
BCG vaccination and multiple sclerosis risk: A Norwegian cohort study
Nakken O, Aarseth JH, Wergeland S, Stigum H, Meyer HE, Holmøy T |
Multiple sclerosis (Houndmills, Basingstoke, England) | 2024 |
|
Boosting Immunogenicity of a Recombinant Mycobacterium smegmatis Strain via Zinc-Dependent Ribosomal Proteins
Singh S, Kanzin D, Chavez S, Saavedra-Avila NA, Ng TW, Lukose R, Mayer O, Kim J, Chen B, Chen M, Porcelli SA, Jacobs WR Jr, Tiwari S |
Biomedicines | 2024 |
|
Efficacy and outcomes of BCG re-vaccination in COVID-19: a systematic review, meta-analysis, and meta-regression of randomized controlled trials
Jain H, Odat RM, Hussein AM, Dey D, Ahmed M, Jain J, Goyal A, Ratnani T, Idrees M, Prajjwal P, Passey S, Yadav R |
Annals of Medicine and Surgery | 2024 |
|
Protocol for analyzing BCG-induced trained immunity in murine bone marrow-derived macrophages
Xu JC, Hu Z, Fan XY |
STAR Protocols | 2024 |
|
Efficacy of BCG Vaccination against COVID-19: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Wen J, Liu Q, Tang D, He JQ |
Journal of Clinical Medicine | 2023 |
|
Recombinant BCG expressing SARS-CoV-2 chimeric protein protects K18-hACE2 mice against viral challenge
Mambelli F, Marinho FV, Andrade JM, de Araujo AC, Abuna RP, Fabri VM, Santos BP, da Silva JS, de Magalhães MT, Homan EJ, Leite LC, Dias GB, Heck N, Mendes DA, Mansur DS, Báfica A, Oliveira SC |
Journal of immunology (Baltimore, Md. : 1950) | 2023 |
|
BCG vaccination policy, natural boosting and pediatric brain and CNS tumor incidences
Singh S, Diwakar A, Singh RK |
Frontiers in immunology | 2023 |
|
Next-Generation TB Vaccines: Progress, Challenges, and Prospects
Zhuang L, Ye Z, Li L, Yang L, Gong W |
Human vaccines | 2023 |
|
BCG administration promotes the long-term protection afforded by a single-dose intranasal adenovirus-based SARS-CoV-2 vaccine
Perera DJ, Domenech P, Babuadze GG, Naghibosadat M, Alvarez F, Koger-Pease C, Labrie L, Stuible M, Durocher Y, Piccirillo CA, Lametti A, Fiset PO, Elahi SM, Kobinger GP, Gilbert R, Olivier M, Kozak R, Reed MB, Ndao M |
iScience | 2023 |
|
Evaluation of the safety and immunological effects of Bacillus Calmette-Guérin in combination with checkpoint inhibitor therapy in a patient with neuroendocrine carcinoma: a case report.
Föhse K, Debisarun PA, Kilic G, van Dodewaard-de Jong JM, Netea MG |
Journal of medical case reports | 2023 |
|
Intravenous BCG vaccination reduces SARS-CoV-2 severity and promotes extensive reprogramming of lung immune cells
Singh AK, Wang R, Lombardo KA, Praharaj M, Bullen CK, Um P, Gupta M, Srikrishna G, Davis S, Komm O, Illei PB, Ordonez AA, Bahr M, Huang J, Gupta A, Psoter KJ, Creisher PS, Li M, Pekosz A, Klein SL, Jain SK, Bivalacqua TJ, Yegnasubramanian S, Bishai WR |
iScience | 2023 |
|
BCG-trained macrophages elicit a protective inflammatory response against the pathogenic bacteria Brucella abortus
de Araujo AC, de Queiroz NM, Marinho FV, Oliveira SC |
Journal of immunology (Baltimore, Md. : 1950) | 2023 |
|
Bacille-Calmette-Guerin modulates human macrophage and dendritic cell response to SARS-CoV-2 S-glycoprotein
Ambe RC, Bhalla S, Alvarado A, Barragan J, Cervantes J |
2023 | |
|
Current Understanding of Bacillus Calmette-Guérin-Mediated Trained Immunity and Its Perspectives for Controlling Intracellular Infections.
de Araujo ACVSC, Mambelli F, Sanches RO, Marinho FV, Oliveira SC |
2023 | |
|
Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonist.
Um PK, Praharaj M, Lombardo KA, Yoshida T, Matoso A, Baras AS, Zhao L, Srikrishna G, Huang J, Prasad P, Kates M, McConkey D, Pardoll DM, Bishai WR, Bivalacqua TJ |
bioRxiv : the preprint server for biology | 2023 |
|
Research progress in the off-target effects of Bacille Calmette–Guérin vaccine
Wu Y, Zhang X, Zhou L, Lu J, Zhu F, Li J |
Chinese Medical Journal | 2023 |
|
Bacillus Calmette–Guérin-Induced Trained Immunity Protects Against SARS-CoV-2 Challenge in K18-hACE2 Mice
Bao-Zhong Zhang, Huiping Shuai, Hua-rui Gong, Jing-Chu Hu, Bingpeng Yan, Terrence Tsz-Tai Yuen, Ye-Fan Hu, Chaemin Yoon, Xiaolei Wang, Yuxin Hou, Xuansheng Lin, Xiner Huang, Renhao Li, Yee-Man Au-Yeung, Wenjun Li, Bingjie Hu, Yue Chai, Ming Yue, Jian-Piao Cai, Guang Ling, Ivan Hung, K.Y. Yuen, Jasper F.W. Chan, Jian-Dong Huang, Hin Chu |
JCI Insight | 2022 |
|
Dynamic single-cell RNA sequencing reveals BCG vaccination curtails SARS-CoV-2 induced disease severity and lung inflammation
Alok K Singh, Rulin Wang, Kara A Lombardo, Monali Praharaj, C Korin Bullen, Peter Um, Stephanie Davis, Oliver Komm, Peter B Illei, Alvaro A Ordonez, Melissa Bahr, Joy Huang, Anuj Gupta, Kevin J Psoter, Sanjay K Jain, Trinity J Bivalacqua, Srinivasan Yegnasubramanian, William R Bishai |
||
|
Harnessing Mycobacterium bovis BCG Trained Immunity to Control Human and Bovine Babesiosis
R Bastos, H Alzan, V Rathinasamy, B Cooke, O Dellagostin, R Barletta, C Suarez |
Human vaccines | 2022 |
|
Trained immunity: A Yin‐Yang balance
Z Hu, S Lu, D Lowrie, X Fan |
2022 | |
|
The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions
K Dheda, T Perumal, H Moultrie, R Perumal, A Esmail, A Scott, Z Udwadia, K Chang, J Peter, A Pooran, A von Delft, D von Delft, N Martinson, M Loveday, S Charalambous, E Kachingwe, W Jassat, C Cohen, S Tempia, K Fennelly, M Pai |
The lancet. Respiratory medicine | 2022 |
|
New Developments in T Cell Immunometabolism and Therapeutic Implications for Type 1 Diabetes
Zhang M, Zhou Y, Xie Z, Luo S, Zhou Z, Huang J, Zhao B |
Frontiers in Endocrinology | 2022 |
|
Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial
Upton CM, van Wijk RC, Mockeliunas L, Simonsson US, McHarry K, van den Hoogen G, Muller C, von Delft A, van der Westhuizen HM, van Crevel R, Walzl G, Baptista PM, Peter J, Diacon AH |
2022 | |
|
The safety of co-administration of Bacille Calmette-Guérin (BCG) and influenza vaccines
Villanueva P, Wadia U, Crawford NW, Messina NL, Kollmann TR, Lucas M, Manning L, Richmond P, Pittet LF, Curtis N |
PloS one | 2022 |
|
Cyclic di-AMP as endogenous adjuvant enhanced BCG-induced trained immunity and protection against Mycobacterium tuberculosis in mice
Ning H, Kang J, Lu Y, Liang X, Zhou J, Ren R, Zhou S, Zhao Y, Xie Y, Bai L, Zhang L, Kang Y, Gao X, Xu M, Ma Y, Zhang F, Bai Y |
Frontiers in immunology | 2022 |
|
A century of BCG vaccination: Immune mechanisms, animal models, non-traditional routes and implications for COVID-19.
Singh S, Saavedra-Avila NA, Tiwari S, Porcelli SA |
Frontiers in immunology | 2022 |
|
Strong tuberculin response after BCG vaccination is associated with low multiple sclerosis risk: a population-based cohort study
Nakken O, Holmøy T, Stigum H, Myhr KM, Dahl J, Heldal E, Meyer HE |
International Journal of Epidemiology | 2022 |
|
BCG and SARS-CoV-2-What Have We Learned?
Kulesza J, Kulesza E, Koziński P, Karpik W, Broncel M, Fol M |
Human vaccines | 2022 |
|
Nanomaterials: small particles show huge possibilities for cancer immunotherapy
Chen Z, Yue Z, Yang K, Li S |
Journal of nanobiotechnology | 2022 |
|
Implications of the non-specific effect induced by Bacillus Calmette-Guerin (BCG) vaccine on vaccine recommendations
Goudouris E, Aranda CS, Solé D |
Jornal de Pediatria | 2022 |
|
Dynamic single-cell RNA sequencing reveals BCG vaccination curtails SARS-CoV-2 induced disease severity and lung inflammation
Singh AK, Wang R, Lombardo KA, Praharaj M, Bullen CK, Um P, Davis S, Komm O, Illei PB, Ordonez AA, Bahr M, Huang J, Gupta A, Psoter KJ, Jain SK, Bivalacqua TJ, Yegnasubramanian S, Bishai WR |
2022 | |
|
Recombinant BCGs for tuberculosis and bladder cancer
AK Singh, G Srikrishna, TJ Bivalacqua, WR Bishai |
Vaccine | 2021 |
|
After 100 Years of BCG Immunization against Tuberculosis, What Is New and Still Outstanding for This Vaccine?
M Flores-Valdez |
Human vaccines | 2021 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)